Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone

Xiaolun Huang; Wenlu Shen; Guihua Chen; Xiaoshun He; Jiefu Huang

doi:10.1007/BF02950930

Your Location：

Home >

Browse articles >

Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone

Updated：2021-08-27

- Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone
- Chinese Journal of Integrative Medicine Vol. 6, Issue 3, Pages: 208-213(2000)
- Affiliations：
  
  1. Department of Organ Transplantation Surgery, The First Affiliated Hospital, Sun Yat-sen University of Medical Sciences,Guangzhou
  2. Center for Organ Transplantation, The First Affiliated Hospital, The West China University of Medical Sciences,china
- Author bio：
- Funds：
  
  This work was supported by the Sciences Foundation of the Ministry of Health Grants (No. C 0103)
- DOI：10.1007/BF02950930
  CLC：
- Published：2000，
Scan for full text
Xiaolun, H., Wenlu, S., Guihua, C. et al. Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone., CJIM 6, 208–213 (2000). https://doi.org/10.1007/BF02950930

Xiaolun Huang, Wenlu Shen, Guihua Chen, et al. Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone. [J]. Chinese Journal of Integrative Medicine 6(3):208-213(2000)
Xiaolun, H., Wenlu, S., Guihua, C. et al. Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone., CJIM 6, 208–213 (2000). https://doi.org/10.1007/BF02950930 DOI：

Xiaolun Huang, Wenlu Shen, Guihua Chen, et al. Treatment of chronic dysfunction of transplantation kidney in rats —by tanshinone, lysimachiae combined with mycophenolate mofetil or cyclosporine alone. [J]. Chinese Journal of Integrative Medicine 6(3):208-213(2000) DOI： 10.1007/BF02950930.

摘要

Objective: To evaluate the relationship between chronic kidney dysfunction after transplantation and chronic vascular rejection (CVR)

and to evaluate the efficacy and safety of Tanshinone (Tan) and Herba Lysimachiae (Lys) combined with Mycophenolate Mofetil (MMF) to fight against CVR

and to reduce the incidence of chronic dysfunction in rat renal transplantation model.Methods: Sixty-five male SD rats as donors and sixty-five male Wistar rats as recipients were used. The recipients were divided into five Groups

including Group A: Lys + Cyclosporine A (CsA)

Group B: Tan+CsA

Group C: MMF+CsA

Group D: CsA

and Group E: normal saline. Kidney function and morphological changes were assessed at 2

and 6 weeks after transplantation. All sections of renal grafts were stained with monoclonal antibodies (McAB)

. including major histocompability complex class II (OX-6)

lymphocyte function antigen-1 (CDllb/CD18)

intercellular adhesive molecular-1 (IA29)

CD8+ (OX-8)

and proliferation cell nuclear antigen (PCNA) (5A10

IgGlk) were used. Results:The two control groups developed typical chronic rejection episodes

and the histologic feature indication of kidney chronic rejection includes loss of renal units and presence of an obliteration arteriopathy involving large renal arteries. These were associated with serum levels of BUN and SCr increased and different degrees of glomerulosclerosis. Their mean survival time was lower than that of other groups. By contrast

serum levels of cytokine in control groups was significantly increased when compared with group B and C (P<0.05). Both group B and C had minimum changes in glomeruli and arteries

and expression levels of PCNA on the glomeruli and tubular cells were higher than those of other groups (P<0. 05). However

there was no significant difference (P>0.05) between group B and C.Conclusions: CVR may activate the risk of the factor responsible for the development of graft chronic dysfunction that causes slow

progressive destruction of the transplanted kidney. Tanshinone was extracted from Salvia miltiorrhiza and purified for use in medicine. Especially when Tanshinone combined with a low-dose of CsA

it may fight against the CVR by inhibiting cell infiltration

and improving microcirculation of the graft

and thus the incidence of CVR is reduced. It is suggested that Tanshinone can be applied to treat patients with chronic renal dysfunction when used in combination with a low-dose Cyclosporine.

Abstract

Objective: To evaluate the relationship between chronic kidney dysfunction after transplantation and chronic vascular rejection (CVR)

and to evaluate the efficacy and safety of Tanshinone (Tan) and Herba Lysimachiae (Lys) combined with Mycophenolate Mofetil (MMF) to fight against CVR

including Group A: Lys + Cyclosporine A (CsA)

Group B: Tan+CsA

Group C: MMF+CsA

Group D: CsA

and Group E: normal saline. Kidney function and morphological changes were assessed at 2

and 6 weeks after transplantation. All sections of renal grafts were stained with monoclonal antibodies (McAB)

. including major histocompability complex class II (OX-6)

lymphocyte function antigen-1 (CDllb/CD18)

intercellular adhesive molecular-1 (IA29)

CD8+ (OX-8)

and proliferation cell nuclear antigen (PCNA) (5A10

IgGlk) were used. Results:The two control groups developed typical chronic rejection episodes

serum levels of cytokine in control groups was significantly increased when compared with group B and C (P<0.05). Both group B and C had minimum changes in glomeruli and arteries

and expression levels of PCNA on the glomeruli and tubular cells were higher than those of other groups (P<0. 05). However

there was no significant difference (P>0.05) between group B and C.Conclusions: CVR may activate the risk of the factor responsible for the development of graft chronic dysfunction that causes slow

progressive destruction of the transplanted kidney. Tanshinone was extracted from Salvia miltiorrhiza and purified for use in medicine. Especially when Tanshinone combined with a low-dose of CsA

it may fight against the CVR by inhibiting cell infiltration

and improving microcirculation of the graft

and thus the incidence of CVR is reduced. It is suggested that Tanshinone can be applied to treat patients with chronic renal dysfunction when used in combination with a low-dose Cyclosporine.

关键词

rat renal transplantationchronic vascular rejectionTanshinoneHerba Lysimachiae

Keywords

rat renal transplantationchronic vascular rejectionTanshinoneHerba Lysimachiae

references

Hayry P, Aavik E, Savolainen H. Mechanisms of chronic rejection. Transplantation Proc 1999; 31(7A): 5–8.

Kurokawa T, Takagi H. Mechanism and prevention of ischemia-reperfusion injury. Transplant Proc 1999; 31:1775 -17769.

Jerzy W, Kupiec W. Chronic allograft rejection. Current opinion in Organ Transplantation 1999;4:1 -2.

Faber J, Lime SH, Morris PJ, et al. Renal transplantation in the rat: Details of technique. The Australian and New Zealand J Surgery 1971; 41 (1): 69–75.

Solez RA, Axelsen B, Hallgrimur BK, et al. International standardization of criteria for the histology diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993;44(suppl):411–422.

Sheng H. A method for studies Immunohistochemistry quantification. J Chin Histochemistry and Cellular Chemistry 1995;4(1): 59–61.

Yang XY. Measure the levels of PCNA expression — different methods affects. Chin J Pathol 1993; 22(2): 74–76.

Foggy ML. Chronic rejection-graft arteriosclerosis. Trans- plantation Proc 1990;22(1): 119–122.

Dimness E, Fellstrom B, Larsson E, et al. Can chronic vas- cular rejection of a renal transplant be predicted? Transplant Proc 1995;27(1):881–883.

Fellstrom B, Backman U, Larsson E, et al. Are their markers to initate treatment of chronic rejection? Transplant Proc 1999; 31: 1796–1798.

Briscoe DM, Ganz PT, Stephen I, et al. The problem of chronic rejection: Influence of leukocyte-endothelial interactions. Kidney Int 1997;51(suppl 58):22–27.

Manikkam SA, Morris RE, Strom TB. Immunosuppressants: Cellular and molecular mechanisms of action. Am J Kidney Dis 1996; 28(2): 159–172.

Huang XL, Shen WL, LI YP, et al. Expression of ICAM-1 and LFA-1 molecules in relation to renal allograft rejection in rats. Chin Med Sci J 1999; 14(3): 163–166.

Huang XL, Shen WL, Zhou ZQ. Medicine S inhibits class II MHC expression of intra-graft kidney in rats. J West Chin Univ of Med 1997;28(2):204–208.

Huang XL, Shen XL, LI YP, et al. Chinese drug S and B inhibited expression of ICAM-1 and LFA-1 in renal allografts during rejection. Chin J Nephrology 1998,14(1): 43–46.

Lemstrom KL, Koskinen PT, Hayry PA. Molecular mechanisms of chronic renal allograft rejection. Kidney Int 1995; 48(suppl 52):2–10.

Park SK, Kang MJ, Kon GY. Renal tubule regeneration after ischemic injury is coupled to the up-regulation and activation of cyclins and cyclin dependent kinases. Kidney Int 1997;52:706–714.

Kurokawa T, Takagi H. Mechanism and prevention of ischemia-reperfusion injury. Transplant Proc 1999; 31:1775 -1779.

Gohra HE, Thomas O, Mcdonald EA, et al. Endothelial loss and regeneration in a model of transplant arteriosclerosis. Transplantation 1995; 60(l):96–102.

Jin HM, GU ZL, Wang XH, et al. Clinical application of Salvia preparation and its therapeutical principle of activating blood circulation to remove stasis. Chin Med J 1978; 3:180–185.

CUI H, WANG X, ZHONG ZH, et al. Effect of Salvia to the (methyl-3H) thymidine nucleotide incorporation to cultured hepatocyte in vitro. Pharmacy Bulletin 1987;22(9): 535.

CHEN LZ, ZHOU BL, WU ZQ, et al. Preliminary observation on Salvia in adjusting experimental hepatic microcirculatory disturbance. CJIM 1988;8(3): 161–165.

Forber JS, Orosz CG, Rose ML, et al. Can graft endothelial cells initiate a host antigraft immune response? Transplantation 1996;61(3): 343–349.

Foung RA, Burdman EA, Johnson RJ, et al. Cyclosporine, an induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 1996;49(3): 1141–1151.

Maria JG, Biol SD, Carla IJ, et al. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Am J Kidney Dis 1996; 28(1): 23–31.

Johnson HA, Bond VP, A method of labeling tissues with tritiated thymidine in vitro and its use in comparing rates of cellular proliferation duct epithelium of the human breast. Cancer 1961; 14:693–642.

Linden MD, Torres FX, Kubus J, et al. Clinical application of morphologic and immunocyto-chemical assessments of proliferation. Am J Clin Pathol 1992;97(suppl I):S4-S8.

Shankcan SJ. Cell-cycle control and renal disease. Kidney Int 1997:52:294–308.

FULL TEXT LINK

More>

Views

386

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Tanshinone IIA: a potent, natural anti-carcinogenic agent for the management of systemic malignancies

Therapeutic strategies for acne and its integrated traditional and western medicine study

Study on biological effect of anti-cancer herbs

Influence of blood-activating drugs on adhesive and invasive capability of tumor cells in lung cancer patients

Application of large dosage of Salvia miltiorrhiza compositae in treating 23 patients of newborn hypoxic ischemic encephalopathy

Related Author

No data

Related Institution

University of Illinois at Chicago

Institute of Dermatology, Dalian Medical University

Traditional Chinese Medicine Tumor Department, Fuzhou General Hospital, Nanjing Military Region

Traditional Chinese Medicine and Oncology Hospital of Fuzhou Weida

Guang’anmen Hospital, China Academy of TCM

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰